Linezolid Accord (Linezolid)

Linezolid belongs to the oxazolidinone class and works by binding to the 23S rRNA of the bacterial 50S ribosomal subunit. This binding blocks the formation of the initiation complex required for protein synthesis, halting bacterial growth. The effect is bacteriostatic for most organisms and can become bactericidal at higher concentrations.

The specific dose and duration of therapy are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals should follow the recommended dosing regimen on the product label or institutional protocol.

Linezolid is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; the decision should be made by the prescriber after weighing benefits and risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Linezolid offers oral bioavailability comparable to intravenous administration, making it convenient for step‑down therapy. Unlike glycopeptides such as vancomycin, it does not require therapeutic drug monitoring and has activity against many resistant Gram‑positive organisms, including MRSA and VRE. However, it may cause hematologic toxicity and requires caution with serotonergic drugs, which differ from the safety profile of some alternatives.

Store Linezolid Accord at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children. Do not store in a refrigerator or freezer.

Linezolid Accord is administered orally as a tablet. It can be taken with or without food, although taking it with food may reduce gastrointestinal upset in some patients. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse events include thrombocytopenia, peripheral neuropathy, serotonin syndrome (especially when combined with serotonergic drugs), lactic acidosis, optic neuritis, and severe anemia. Patients should be monitored regularly for blood‑cell abnormalities, neurological symptoms, and signs of metabolic disturbances, and any concerning signs should prompt immediate medical evaluation.

Linezolid Accord should be avoided in individuals with known hypersensitivity to linezolid or any oxazolidinone. It is contraindicated in patients currently receiving monoamine oxidase inhibitors (MAOIs) and should be used with caution in those taking serotonergic agents due to the risk of serotonin syndrome. Clinicians should also assess renal and hepatic function before initiating therapy.